152 related articles for article (PubMed ID: 2897264)
1. Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin.
Keeling CA; Basso LV
Clin Nucl Med; 1988 Apr; 13(4):260-3. PubMed ID: 2897264
[TBL] [Abstract][Full Text] [Related]
2. Detection of metastatic medullary thyroid cancer with 131I-MIBG scans in Sipple's syndrome.
Itoh H; Sugie K; Toyooka S; Kawase M; Mukaino S; Hazama F; Endo K; Torizuka K; Nakao K; Imura H
Eur J Nucl Med; 1986; 11(12):502-4. PubMed ID: 2874028
[TBL] [Abstract][Full Text] [Related]
3. Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.
Poston GJ; Thomas AM; Macdonald DW; Karvounaris D; Henderson BL; George P; Lynn JA; Lavender JP
Nucl Med Commun; 1986 Apr; 7(4):215-21. PubMed ID: 2873544
[TBL] [Abstract][Full Text] [Related]
4. Thyroid uptake of MIBG in Sipple's syndrome.
Perdrisot R; Rohmer V; Lejeune JJ; Bigorgne JC; Jallet P
Eur J Nucl Med; 1988; 14(1):37-8. PubMed ID: 2898364
[TBL] [Abstract][Full Text] [Related]
5. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine.
Sone T; Fukunaga M; Otsuka N; Morita R; Muranaka A; Yanagimoto S; Tomomitsu T; Nakayama H; Harada T
J Nucl Med; 1985 Jun; 26(6):604-8. PubMed ID: 3158726
[TBL] [Abstract][Full Text] [Related]
6. Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study.
Baulieu JL; Guilloteau D; Delisle MJ; Perdrisot R; Gardet P; Delépine N; Baulieu F; Dupont JL; Talbot JN; Coutris G
Cancer; 1987 Nov; 60(9):2189-94. PubMed ID: 2894239
[TBL] [Abstract][Full Text] [Related]
7. Imaging of medullary thyroid cancer with 131I-MIBG.
Endo K; Shiomi K; Kasagi K; Konishi J; Torizuka K; Nakao K; Tanimura H
Lancet; 1984 Jul; 2(8396):233. PubMed ID: 6146795
[No Abstract] [Full Text] [Related]
8. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
[TBL] [Abstract][Full Text] [Related]
9. Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma.
Oishi S; Sasaki M; Sato T; Hirota Y; Takahashi M
Endocrinol Jpn; 1986 Jun; 33(3):309-15. PubMed ID: 2875869
[TBL] [Abstract][Full Text] [Related]
10. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
11. Pitfall of Sipple's syndrome diagnosis by 131I-metaiodobenzylguanidine (MIBG).
Talbot JN; Coutris G; Moulonguet M; Hoang C; Perniceni T; Milhaud G
J Nucl Med Allied Sci; 1987; 31(4):337-40. PubMed ID: 2895168
[No Abstract] [Full Text] [Related]
12. Medullary thyroid carcinoma: localization of a mediastinal metastasis with I-131 MIBG.
Laflamme L; Taillefer R; Duranceau A; Verdy M; Schürch W
Clin Nucl Med; 1988 Aug; 13(8):577-9. PubMed ID: 2901928
[TBL] [Abstract][Full Text] [Related]
13. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
14. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
[TBL] [Abstract][Full Text] [Related]
16. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine.
Clarke SE; Lazarus CR; Edwards S; Murby B; Clarke DG; Roden TM; Fogelman I; Maisey MN
J Nucl Med; 1987 Dec; 28(12):1820-5. PubMed ID: 3681441
[TBL] [Abstract][Full Text] [Related]
17. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine.
Ansari AN; Siegel ME; DeQuattro V; Gazarian LH
J Nucl Med; 1986 Dec; 27(12):1858-60. PubMed ID: 2878066
[TBL] [Abstract][Full Text] [Related]
18. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.
Wiseman GA; Kvols LK
Semin Nucl Med; 1995 Jul; 25(3):272-8. PubMed ID: 7570046
[TBL] [Abstract][Full Text] [Related]
19. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
Bomanji J; Mather S; Moyes J; Ellison D; Grossman A; Britton KE; Besser GM
J Nucl Med; 1992 Jun; 33(6):1121-4. PubMed ID: 1597726
[TBL] [Abstract][Full Text] [Related]
20. Uptake of 131I-MIBG by medullary carcinoma of thyroid in familial cases.
Coutris G; Talbot JN; Kabla G; Calmettes C; Milhaud G
Eur J Nucl Med; 1986; 12(2):77-9. PubMed ID: 3732310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]